Insulin glargine is a synthetic long-acting insulin analog used primarily in the management of diabetes mellitus. It is produced through recombinant DNA technology in non-pathogenic strains of Escherichia coli. Chemically, it belongs to the class of peptide hormones, specifically designed to mimic the action of endogenous insulin with modifications that prolong its duration of action. Researchers have developed insulin glargine to provide a more stable and prolonged glucose-lowering effect compared to regular human insulin.
The primary physiological role of insulin glargine is to regulate blood glucose levels by facilitating cellular uptake of glucose, particularly in muscle and adipose tissue, and by inhibiting hepatic glucose production. Research areas include its efficacy in reducing HbA1c levels, its impact on hypoglycemia risk, and its role in long-term diabetes management. Studies have also explored its use in combination with other antidiabetic agents to optimize glycemic control.
Insulin glargine acts on the insulin receptor, a transmembrane receptor that triggers the insulin signaling pathway. Upon binding, it activates the receptor's intrinsic tyrosine kinase activity, leading to a cascade of phosphorylation events that promote glucose uptake and metabolism. This pathway involves key intermediates such as insulin receptor substrates (IRS) and phosphoinositide 3-kinase (PI3K), ultimately enhancing glucose transporter type 4 (GLUT4) translocation to the cell membrane.
Pharmacokinetically, insulin glargine has a prolonged half-life of approximately 24 hours when administered subcutaneously, allowing for once-daily dosing. It is metabolized in the liver and kidneys into active metabolites. Its bioavailability is nearly complete when given subcutaneously, but it is not suitable for oral administration due to degradation in the gastrointestinal tract.
Clinically, insulin glargine is widely used for both type 1 and type 2 diabetes management. It is approved by regulatory agencies such as the FDA, EMA, and TGA for this purpose. Researchers have found it effective in maintaining basal insulin levels with a reduced risk of nocturnal hypoglycemia compared to other insulins. It is available under various brand names, including Lantus, Toujeo, and Basaglar, and is subject to prescription regulations in many countries.